BullMarket.com Updates Outlooks on CRO Stocks
February 08 2010 - 10:19AM
PR Newswire (US)
PRINCETON, N.J., Feb. 8 /PRNewswire/ -- BullMarket.com
(http://www.bullmarket.com/), an online investment newsletter
focused on long-term growth and income-generating stocks, has
provided subscribers with coverage of clinical research
organization (CRO) stocks, including Covance (NYSE:CVD), Parexel
(NASDAQ:PRXL), Charles River Laboratories (NYSE:CRL),
Pharmaceutical Product Development (NASDAQ:PPDI), and Kendle
International (NASDAQ:KNDL). All paid and trial subscribers to
BullMarket.com can now receive immediate access to the newsletter's
exclusive daily reports. As a subscriber, you'll also gain access
to our Recommended List of stocks, which was up 40% in 2009 and
also outperformed the S&P by 15% in 2008. Start your 14-day
free trial today:
https://www.bullmarket.com/subscribe/pr/?refer=BMR687P In its daily
report, BullMarket.com wrote: "Covance CEO Joseph Herring conceded
that 2009 was a difficult year, but he argued that the company made
positive progress on many fronts. He cited its 11% revenue growth
on a constant currency basis; its solid book-to-bill ratio; and
market share gains across the board. He also noted Covance's
successful integration of the Greenfield lab, which analysts
generally consider to have been a good deal for the company."
BullMarket.com looked at the following topics, among others: -- At
what price would BullMarket.com be buyers of Covance's stock? --
Why has Parexel's outlook been stronger than many of its peers? --
Why does Pharmaceutical Product Development look well positioned to
rebound in the second half of the year? -- Why would BullMarket.com
currently be staying on the sidelines with Charles Rivers and
Kendle? About BullMarket.com: Launched in 1997, BullMarket.com has
a strong track record of creating wealth for its subscribers by
providing sound, long-term investing advice. The BullMarket.com
Recommended List includes about 50 companies across all major
industries, including Financials, Healthcare, Energy, Technology,
and Retail, among others. BullMarket.com is one of the oldest
continuously published investment newsletters online, and its
Recommended List has consistently outperformed the major market
indices. NOTE: This release was published by Indie Research
Advisors, LLC, a registered investment advisor with CRD #131926.
Interested parties may visit adviserinfo.sec.gov for additional
information. Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an
offer or solicitation to buy or sell any security. Contact: Indie
Research Advisors, LLC Marcie Martin, +1-888-278-5515 DATASOURCE:
Indie Research Advisors, LLC CONTACT: Marcie Martin, Indie Research
Advisors, LLC, +1-888-278-5515 Web Site: http://www.bullmarket.com/
Copyright